in the absence of a submission from the holder of the marketing authorisation
abatacept (Orencia®) is not recommended for use within NHS Scotland.
Indication under review: Treatment of highly active and progressive disease in adult patients with rheumatoid arthritis not previously treated with methotrexate.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result we cannot recommend its use within NHSScotland.
|Drug Name:||abatacept (Orencia)|
|SMC Drug ID:||1230/17|
|Manufacturer:||Bristol-Myers Squibb Pharmaceuticals Ltd|
|Indication:||Treatment of highly active and progressive disease in adult patients with rheumatoid arthritis not previously treated with methotrexate.|
|Sub Category:||10.1 Drugs used in rheumatic diseases and gout|
|Submission Type:||Non submission|
|Date Advice Published:||13 March 2017|